Pharmaceutical Cannabis - Switzerland

Switzerland

Switzerland is positioned to witness a significant increase in revenue within the Pharmaceutical Cannabis market, with projections indicating a figure of US$25.08m by 2024.
The expected annual growth rate (CAGR 2024-2029) is forecasted at 5.00%, leading to a market volume of US$32.01m by 2029.
Among global counterparts, the United States will lead in revenue generation, with an estimated US$913.10m in 2024.
In terms of per capita calculations, the revenue generated per person in 2024 stands at US$6.86k.
Switzerland's Pharmaceutical Cannabis market is flourishing, attracting investors due to its strict regulations ensuring high-quality products and research opportunities.

Key regions: United States, Spain, Europe, Thailand, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Switzerland has seen a significant development in its Pharmaceutical Cannabis market, with an increasing number of consumers turning to cannabis-based products for medicinal purposes.

Customer preferences: Consumers in Switzerland are showing a growing preference for Pharmaceutical Cannabis products due to their perceived health benefits and effectiveness in treating various medical conditions. The shift towards natural and alternative medicines has also played a role in driving the demand for Pharmaceutical Cannabis in the country.

Trends in the market: One notable trend in the Swiss Pharmaceutical Cannabis market is the increasing acceptance and legalization of medical cannabis. This has led to a wider availability of Pharmaceutical Cannabis products in pharmacies and healthcare facilities across the country. Additionally, the market has seen a rise in research and development activities focused on creating innovative cannabis-based medications to cater to specific medical needs.

Local special circumstances: Switzerland's unique regulatory environment, which allows for the cultivation and sale of low-THC Cannabis products, has created a conducive market for Pharmaceutical Cannabis companies to operate in. The country's progressive stance on medical cannabis and its well-established pharmaceutical industry have also contributed to the growth of the Pharmaceutical Cannabis market in Switzerland.

Underlying macroeconomic factors: The stable economy and high disposable income levels in Switzerland have made it a lucrative market for Pharmaceutical Cannabis companies looking to expand their operations. Additionally, the country's strong healthcare infrastructure and emphasis on research and development have created favorable conditions for the growth of the Pharmaceutical Cannabis market.

Methodology

Data coverage:

Data encompasses B2B and B2C enterprises. Figures are based on companies' revenues, funding values and global consumer survey data. Revenues include retail, sales and taxes.

Modeling approach / Market size:

Market sizes are determined by a Top-Down approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports, third-party data. Next, we use relevant key market indicators and data from country-specific associations such as tobacco spending per capita, medical product spending per capita, consumer spending and consumer spending for recreation purposes, population. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.